Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.
about
Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, PeruAdverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective studyAntitubercular therapy in patients with cirrhosis: challenges and optionsClinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, BrazilCutaneous tuberculosis: diagnosis, histopathology and treatment - part II.A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of hostPsychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish LarvaeTreatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis.Tuberculosis among HIV-infected patients in Stockholm, Sweden, 1987-2010: treatment outcomes and adverse reactions.Kinetics and mechanism of oxidation of the anti-tubercular prodrug isoniazid and its analog by iridium(iv) as models for biological redox systems.Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population.Challenges of antituberculosis treatment in patients with difficult clinical conditions.Comment on Wang et al.: One-stage posterior focus debridement, interbody graft using titanium mesh cages, posterior instrumentation and fusion in the surgical treatment of lumbo-sacral spinal tuberculosis in the aged.
P2860
Q28478014-A5FCDD1A-0F28-4E30-A2C6-4BC79EACB4FFQ28533626-CAA45311-E1B5-4D42-8C8A-B4AB4E85DDB2Q33626827-1FA3021C-36BB-427A-B0C1-9D6E4D8B1F8CQ33823893-C6B04ECD-E88F-4DCB-8B98-18F856083A24Q34104786-9F093016-0A65-46C1-9BEE-104CEA6BCDF4Q36774253-BDD60042-3818-492E-A26A-2ADA83402DB1Q36830922-C05EFC96-0237-4B32-A0FB-6F9A3914599CQ37428683-3DF64609-9540-4A59-BF49-FF692F6C7170Q38207924-93A83F7D-6D86-4678-9EA8-3553BB26B180Q38220765-76910442-557A-469A-B783-C46B4FB56A3FQ38360770-4C444278-CA33-4A98-84AD-C0180C878347Q38369608-B8885EDA-2555-4BCD-9F33-D17C4EB24D20Q38824529-FED6BC32-E444-4536-A9E0-90FA67B04CD6Q38851516-0A00F6BB-1652-4A84-BA68-EE91D0B8BA76Q38957578-CBCEF438-A3E3-48F4-BD32-2DFD5B667DBEQ38977166-ECCC4D19-613C-4BB0-8A20-85B927BB6D87Q40086314-EF941EE0-8D17-46CC-95D0-6DD25439172BQ42237993-2F4F8C16-B7C9-4E78-BF60-98808AF55216Q46349091-7A182DA9-7A42-43AB-AEA7-3DF99A3306D7Q51653421-6ACD604E-7B60-4D49-B3D0-62E42D8EEA30Q53095226-545B86E9-5032-4C52-8E28-D652816D307FQ54611264-081589BC-5164-4699-AEB6-D5B33A26E9EB
P2860
Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@en
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@nl
type
label
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@en
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@nl
prefLabel
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@en
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@nl
P2093
P2860
P1476
Antituberculosis drugs: drug i ...... ons. Part 1: first-line drugs.
@en
P2093
Fernando Augusto Fiúza de Mello
Hélio Ribeiro de Siqueira
Marcos Abdo Arbex
Marília de Castro Lima Varella
P2860
P304
P356
10.1590/S1806-37132010000500016
P577
2010-09-01T00:00:00Z